At SITC 2026 (Phoenix, November 4–8), Brenus Pharma and Champions Oncology presented their collaboration evaluating STC-1010, an active immunotherapy, in patient-derived 3D tumor cultures, an innovative approach to study tumor–immune dynamics and biomarkers of response in “cold” solid tumors.
Most metastatic colorectal cancers are microsatellite stable (MSS): “cold” tumors with no approved immunotherapy today. Brenus is evaluating STC-1010, an in vivo DC-engager, in this population in first line alongside standard of care (Phase I/II BreAK CRC-001 study; NCT06934538). Phase Ia results presented at ESMO 2026 showed no dose-limiting toxicities and 100% disease control at 6 months, with intratumoral immune infiltration.
“With Champions, we established a clinically annotated TumorGraft3D model (CTG-0359) mirroring most our BreAK CRC-001 patients: MSS, KRAS-mutant, BRAF wild-type, with liver metastases. We showed that STC-1010-primed CD8+ T cells reduced tumor viability by up to ~50% and increased tumor apoptosis. By linking STC-1010’s mode of action to real patient conditions and characteristics, our collaboration lays the groundwork for a biomarker-driven strategy in later-stage trials.”
"with Champions, we established a clinically annotated TumorGraft3D model (CTG-0359) mirroring most our BreAK CRC-001 patients: MSS, KRAS-mutant, BRAF wild-type, with liver metastases. We showed that STC-1010-primed CD8+ T cells reduced tumor viability by up to ~50% and increased tumor apoptosis. By linking STC-1010’s mode of action to real patient conditions and characteristics, our collaboration lays the groundwork for a biomarker-driven strategy in later-stage trials.” Said Benoit Pinteur, PharmD, Chief Scientific Officer, Brenus Pharma
"Using patient-derived 3D tumor cultures to evaluate active immunotherapies remains largely unexplored. We are excited to collaborate with Brenus Pharma on this while we work to bridge the translational gaps in immuno-oncology research tools,” said Maria Mancini, PhD, Chief Operating Officer, Champions Oncology.
Scientific ressources :
Link to poster (Nov. 6, 2026): “Development of a biologically aligned ex vivo TumorGraft3D platform to evaluate STC-1010-mediated immune priming and colorectal tumor killing.” First author: Prof. Ignacio Melero, Clínica Universidad de Navarra.
About Brenus Pharma : Brenus Pharma develops an off-the-shelf platform advancing novel modalities in immuno-oncology. This precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response adapting to tumor evolution in hard-to-treat solid tumors, where current therapies fall short. www.brenus-pharma.com, contact@brenus-pharma.com,
About Champions Oncology : Champions Oncology is a global preclinical research services provider that offers end-to-end oncology R&D solutions and innovative data platforms to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Contacts
Brenus Pharma contact@brenus-pharma.com
Champions Oncology gcooper@championsoncology.com
.png)